Abstract
Summary
The Partnering Agreements with Valeant 2005-2012 report provides an
in-depth insight into the partnering interests and activites of one of the
worlds leading biopharma companies.
This report provides all the information you require to better understand
Valeant and its partnering interests and activities over the past seven years.
On demand company reports are prepared upon purchase to ensure inclusion of
the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of
order. If print or CD-Rom version purchased, the report will be sent by
courier using express service.
Description
This report provides all the information you require to better understand
Valeant and its partnering interests and activities over the past seven years.
One of the key aspects of partnering is finding those companies that are
potential partners for the development and commercialization of the next
generation of therapies as developed by innovative biopharma R&D companies. A
lot of resources are spent on finding partners, identifying their
interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their
partnering activities to deliver the company's business development objectives.
The initial chapters of this report provide an orientation of bigpharma's
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 lists the top 50 leading biopharma companies based on
2010 pharmaceutical revenues and their respective partnering activity. Chapter
3 provides an overview of the leading partnering and M&A 2005 to present date
based on headline value.
Chapter 4 provides details on how to approach bigpharma companies with
partnering opportunities whilst chapter 5 lists forthcoming partnering events
and conferences where bigpharma companies will be present to discuss
opportunities face to face.
The main body of the report is provided in chapter 6. A profile of the company
provides everything required to assess the suitability of a company as a
prospective partner. This includes a company overview, partnering interests,
partnering activity according to deal type, industry sector, phase of
development, and therapy area. The profile also includes in-depth contact
information for individuals within the business development function.
The deals are listed by deal type, stage of development and therapy focus,
allowing easy access to deals and alliances of interest. Every deal record
links to an online, live version of the deal record at the Current Agreements
deals and alliances database. Where available, deal records also include the
contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner
to determine under what terms a prospective partner agrees to a partnering
relationship.
Understanding the flexibility of prospective partners' negotiated deals terms
provides critical insight into the negotiation process in termsof what you can
expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions
about a prospective partner's flexibility on a wide range of important issues,
many of which will have a significant impact on each parties ability to derive
value from the deal.
In summary, the report provides the user with the tools to make successful
contact with the right partners effectively and efficiently.
Benefits
Partnering Agreements with Valeant report provides the user with the
following key benefits:
- Detailed company profile of the company
- Partnering interests and therapy focus revealed
- Partnering activity since 2005 - number of deals per year
- Partnering activity for 2005-present
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Detailed listing of all partnering deals since 2005
- Comprehensive access to actual contracts entered into by the company and
its partners*
- Insight into the terms included in a partnering agreement
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Biopharma top 50 and dealmaking activity
- 2.1 Biopharma partnering activity
- 2.2 Biopharma M&A activity
Chapter 3 - Top bigpharma deals by value
- 3.1 Bigpharma M&A
- 3.2 Bigpharma partnering
Chapter 4 - Submitting Opportunities to Prospective Partners
- 4.1 How to submit an opportunity
- 4.2 Opportunity submission template
- 4.3 Sending emails
- 4.4 Face to face at partnering events
- 4.5 Online submission forms
Chapter 5 - Forthcoming partnering events
Chapter 6 - Company Profile
- 6.1 How to use company profiles
- 6.2 Field definitions
- 6.3 Company profile Partnering deals directory (2005-present) - by
industry sector
- Bigpharma
- Pharmaceutical
- Biotech
- Diagnostic
- Drug delivery
- Government
- Medical device
- Consumer health
- Specialty pharma
- Generic pharma
- Agricultural
- Animal health
- Academic
- Non-profit
- Research tools
- Services
- Partnering deals directory (2005-present) - By deal type
- Asset purchase
- Co-Development
- Co-Market
- Co-Promotion
- Collaborative R&D
- Contract service
- Development
- Distribution
- Evaluation
- Joint venture
- Licensing
- Manufacture
- Marketing
- Promotion
- Research
- Royalty financing
- Supply
- Partnering deals directory (2005-present) - M&A
- Partnering deals directory (2005-present) - By stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- Formulation
- Partnering deals directory (2005-present) - By therapy area
- Hospital care
- Cardiovascular
- Central nervous system
- Cosmetic
- Dental
- Dermatology
- Gastrointestinal
- Genetic disorders
- Genitourinary
- Hemotology
- Immunology
- Infectives
- Inflammatory
- Metabolic
- Musculoskeletal
- Oncology
- Ophthalmics
- Respiratory
- Sensory organ
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
- Order Form - Partnering Agreements
- Company Profiles
TABLE OF FIGURES
- Figure 1: Bigpharma partnering activity - top 50 by pharma sales
- Figure 2: Bigpharma M&A activity - top 50 by pharma sales
- Figure 3: Leading M&A deals involving bigpharma by value, 2005-2012
- Figure 4: Leading partnering deals by value, 2005-2012
- Figure 5: Typical partnering opportunity submission template
- Figure 6: Company profile template and definitions used in report
- Figure 7: Dealmaking frequency 2005-2012
- Figure 8: Current partner companies (2005-present)
- Figure 9: Partnering deals by type (2005-present)
- Figure 10: Recent deals (2005-present) by industry sector
- Figure 11: Recent deals (2005-present) by deal type
- Figure 12: Recent deals (2005-present) by stage of development
- Figure 13: Recent deals (2005-present) by therapy area
Partnering Agreements with Valeant 2005-2012 published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 100 Pages and the price starts from US $ 995.
